JP
ESPR

John Paulson’s Esperion Therapeutics ESPR Stock Holding History

John Paulson’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-210,500
Closed -$9.74M – 65
2017
Q2 		$9.74M Sell
210,500
-21,300
-9% -$783K 0.13% 63
2017
Q1 		$8.19M Buy
231,800
+129,800
+127% +$2.97M 0.11% 60
2016
Q4 		$1.28M Hold
102,000
– – 0.02% 90
2016
Q3 		$1.41M Hold
102,000
– – 0.02% 88
2016
Q2 		$1.01M Hold
102,000
– – 0.01% 79
2016
Q1 		$1.73M Buy
102,000
+79,500
+353% +$1.28M 0.01% 85
2015
Q4 		$501K Buy
+22,500
New +$568K ﹤0.01% 73

Other funds holding ESPR

MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

John Paulson's ESPR Position: Q3 2017 in Review

John Paulson sold out of Esperion Therapeutics (ESPR) in Q3 2017, closing a stake of 210,500 shares — an estimated $9.74M sold.

John Paulson first reported a position in ESPR in Q4 2015 and held it in 7 quarters. The position peaked at $9.74M in Q2 2017. 150 funds tracked by Wall St. Rank hold ESPR as of Q3 2017.

  • John Paulson reported no remaining Esperion Therapeutics position as of Q3 2017 after selling out during the quarter.
  • John Paulson sold 210,500 Esperion Therapeutics shares in Q3 2017, an estimated $9.74M.
  • John Paulson first reported a position in Esperion Therapeutics in Q4 2015 and held it in 7 quarters.
  • John Paulson's Esperion Therapeutics position peaked at $9.74M in Q2 2017.
  • 150 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.